stockrowMoolec Science SA
MLEC Healthcare Biotechnology
Moolec Science SA’s revenue for fiscal 2025 (year ended June 2025) was $333.6 million, up 5,830.7% from fiscal 2024.
- Revenue
- +948.4%
- EPS
- −20.0%
- Free cash flow
- +4.48%
Quarter to December 2025, against a year earlier
Follow MLEC
Alert me
Moolec Science SA (MLEC) Piotroski F-score
Moolec Science SA's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (19.31%) | (1.50%) | Fail | 0 |
| Positive operating cash flow | 3.64m | 39.56m | Pass | 1 |
| Rising return on assets | (19.31%) | (1.50%) | Fail | 0 |
| Cash flow above net income | 115.10m | 46.87m | Pass | 1 |
| Falling long-term leverage | 0.03 | 0.44 | Pass | 1 |
| Rising current ratio | 0.13 | 1.03 | Fail | 0 |
| No new shares issued | 430,864 | 252,469 | Fail | 0 |
| Rising gross margin | 39.02% | 3,324.51% | Fail | 0 |
| Rising asset turnover | 0.58 | 0.01 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| MLEC Moolec Science SA | 4 |
| JAGX Jaguar Animal Health, Inc. compare | 3 |
| VBIO Valion Bio, Inc. compare | 3 |
| SPRC SciSparc Ltd. compare | 3 |
| BBLG Bone Biologics Corp. compare | — |
| BPTH Bio-Path Holdings, Inc. compare | — |
| CDT CDT Equity Inc. compare | — |
| ATXI Avenue Therapeutics, Inc. compare | — |
| LNAI Lunai Bioworks Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover